FDA Approves Immunotherapy for MSI-High or MMR-Deficient Tumors – Cancer Network
Cancer Network |
FDA Approves Immunotherapy for MSI-High or MMR-Deficient Tumors
Cancer Network The US Food and Drug Administration (FDA) has granted accelerated approval to pembrolizumab (Keytruda) for pediatric and adult patients with microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient solid tumors. The indication is for … Urothelial Carcinoma Experts Optimistic for Durvalumab/Tremelimumab Combo FDA clears Merck's Keytruda based on cancer genetics, not location FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type |
